Inventor · disambiguated record
Charles-Henry Fabritius
Also filed as: FABRITIUS CHARLES-HENRY · FABRITIUS CHARLES-HENRY ROBERT YVES
9 granted patents·11 pending applications·9 citations·filing 2010–2025
78Inventor score
Files withRYVU THERAPEUTICS S A6TOLREMO THERAPEUTICS AG4NODTHERA LTD3SELVITA S A3FELICITEX THERAPEUTICS INC1
Top patents by PatentIndex Score
20 records- 0177US12344606B2Next-generation modulators of stimulator of interferon genes (STING)RYVU THERAPEUTICS S A·Filed 2020·Granted Jul 1, 2025·2 cites·11 claims
- 0274US9221838B2Inhibitors of AKT activityZHANG LIXIN·Filed 2010·Granted Dec 29, 2015·4 cites·16 claims
- 0367US12162863B2Modulators of stimulator of interferon genes (STING)RYVU THERAPEUTICS S A·Filed 2019·Granted Dec 10, 2024·2 cites·11 claims
- 0457US10577365B2Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinasesFELICITEX THERAPEUTICS INC·Filed 2017·Granted Mar 3, 2020·1 cites·14 claims
- 0557US2025313561A1Next-generation modulators of stimulator of interferon genes (sting)RYVU THERAPEUTICS S A·Filed 2025·Application pending·0 cites
- 0653US12247011B2Selective inhibitors of NLRP3 inflammasomeNODTHERA LTD·Filed 2018·Granted Mar 11, 2025·0 cites·18 claims
- 0753US2025223263A1Selective inhibitors of nlrp3 inflammasomeNODTHERA LTD·Filed 2025·Application pending·0 cites
- 0850US2024327394A1Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancerTOLREMO THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0947US12478624B2Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancerTOLREMO THERAPEUTICS AG·Filed 2020·Granted Nov 25, 2025·0 cites·8 claims
- 1047US12472179B2Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancerTOLREMO THERAPEUTICS AG·Filed 2021·Granted Nov 18, 2025·0 cites·18 claims
- 1139US2023255966A1A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclcTOLREMO THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1238US2023076506A1Heterocyclic compounds as modulators of stimulator of interferon genes (sting)RYVU THERAPEUTICS S A·Filed 2020·Application pending·0 cites
- 1338US2023055741A1Functionalized heterocyclic compounds as modulators of stimulator of interferon genes (sting)RYVU THERAPEUTICS S A·Filed 2020·Application pending·0 cites
- 1437US12351570B2Disubstituted alkyne derivativesMERCK PATENT GMBH·Filed 2019·Granted Jul 8, 2025·0 cites·17 claims
- 1534US11345669B2Urea derivatives and methods of use thereofNODTHERA LTD·Filed 2018·Granted May 31, 2022·0 cites·20 claims
- 1629US2020369665A1Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptorRYVU THERAPEUTICS S A·Filed 2018·Application pending·0 cites
- 1727US2016009697A1Pyridine derivatives as 5-ht6 receptor antagonistsSELVITA S A·Filed 2014·Application pending·0 cites
- 1825US2018305331A1Pyridone derivatives and their use as kinase inhibitorsSELVITA S A O·Filed 2016·Application pending·0 cites
- 1917US2018118718A1Substituted Quinoxaline DerivativesSELVITA S A·Filed 2016·Application pending·0 cites
- 2017US2018148429A1Substituted quinoxaline derivativesSELVITA S A·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles-Henry Fabritius files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →